Cumberland Pharmaceuticals Inc.
CPIX
$6.29
-$0.33-4.99%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 1.59% | -98.28% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1.59% | -98.80% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 1.59% | -98.57% | |||
| SG&A Expenses | 9.65% | -77.32% | |||
| Depreciation & Amortization | 2.86% | -99.31% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.45% | -79.43% | |||
| Operating Income | -7.78% | -113.86% | |||
| Income Before Tax | -8.61% | -103.10% | |||
| Income Tax Expenses | 0.00% | -83.19% | |||
| Earnings from Continuing Operations | -8.60% | -100.08% | |||
| Earnings from Discontinued Operations | -172.92% | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 26.92% | -115.29% | |||
| Net Income | -30.00% | -133.02% | |||
| EBIT | -7.78% | -113.86% | |||
| EBITDA | -88.68% | -402.92% | |||
| EPS Basic | -29.79% | -132.94% | |||
| Normalized Basic EPS | -8.46% | -107.29% | |||
| EPS Diluted | -31.01% | -132.94% | |||
| Normalized Diluted EPS | -8.46% | -107.29% | |||
| Average Basic Shares Outstanding | 0.14% | 0.02% | |||
| Average Diluted Shares Outstanding | 0.14% | 0.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||